Background:

NF-kappa-B is a pleiotropic transcription factor which is present in almost all cell types and is involved in many biological processed such as inflammation, immunity, differentiation, cell growth, tumorigenesis and apoptosis. NF-kappa-B is a homo- or heterodimeric complex formed by the Rel-like domain-containing proteins RELA/p65, RELB, NFKB1/p105, NFKB1/p50, REL and NFKB2/p52. The dimers bind at kappa-B sites in the DNA of their target genes and the individual dimers have distinct preferences for different kappa-B sites that they can bind with distinguishable affinity and specificity. Different dimer combinations act as transcriptional activators or repressors, respectively. NF-kappa-B is controlled by various mechanisms of post-translational modification and subcellular compartmentalization as well as by interactions with other cofactors or corepressors. NF-kappa-B complexes are held in the cytoplasm in an inactive state complexed with members of the NF-kappa-B inhibitor (I-kappa-B) family. In a conventional activation pathway, I-kappa-B is phosphorylated by I-kappa-B kinases (IKKs) in response to different activators, subsequently degraded thus liberating the active NF-kappa-B complex which translocates to the nucleus. NF-kappa-B heterodimeric RelB-p50 and RelB-p52 complexes are transcriptional activators.

Applications:

WB, IHC

Name of antibody:

RELB (Phospho-Ser573)

Immunogen:

Synthetic peptide of human RELB (Phospho-Ser573)

Full name:

v-rel reticuloendotheliosis viral oncogene homolog B (Phospho-Ser573)

Synonyms：

IREL; I-REL; REL-B

SwissProt:

Q01201

IHC positive control:

Human breast carcinoma

IHC Recommend dilution:

50-100

WB Recommended dilution:

500-1000

WB Positive control:

HUVEC cells untreated or treated with TNF

WB Predicted band size:

70 kDa